Spero Therapeutics (SPRO) Common Equity (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Common Equity came in at $52.9 million in Q1 2026, up 56.54% YoY from $33.8 million in Q1 2025, and down 10.31% on a QoQ basis from $59.0 million in Q4 2025.
Spero Therapeutics (SPRO) Common Equity (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Common Equity data on file, last reported at $52.9 million in Q1 2026.
- Quarterly Common Equity rose 56.54% year-over-year to $52.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.9 million (up 56.54% YoY) and the FY2025 annual result came in at $59.0 million, up 27.96% from the prior year.
- Common Equity declined to $52.9 million in Q1 2026, from $59.0 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $106.9 million in Q4 2023 to a low of $26.5 million in Q3 2025.
- A 5-year average of $57.7 million and a median of $54.8 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity slumped 70.97% — and 2023, when it soared 65.33%.
- Tracing SPRO's Common Equity over 5 years: stood at $75.9 million in 2022, then soared by 40.77% to $106.9 million in 2023, then tumbled by 56.85% to $46.1 million in 2024, then rose by 27.96% to $59.0 million in 2025, then dropped by 10.31% to $52.9 million in 2026.
- The last three Common Equity figures came in at $52.9 million (Q1 2026), $59.0 million (Q4 2025), and $26.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 44.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.20 Mn |
| Mar 31, 2026 | 52.93 Mn |
| Dec 31, 2025 | 59.02 Mn |
| Sep 30, 2025 | 26.49 Mn |
| Jun 30, 2025 | 32.83 Mn |
| Mar 31, 2025 | 33.81 Mn |
| Dec 31, 2024 | 46.12 Mn |
| Sep 30, 2024 | 65.51 Mn |
| Jun 30, 2024 | 80.50 Mn |
| Mar 31, 2024 | 96.25 Mn |
| Dec 31, 2023 | 106.89 Mn |
| Sep 30, 2023 | 53.71 Mn |
| Jun 30, 2023 | 54.78 Mn |
| Mar 31, 2023 | 64.84 Mn |
| Dec 31, 2022 | 75.93 Mn |
| Sep 30, 2022 | 32.48 Mn |
| Jun 30, 2022 | 35.92 Mn |
| Mar 31, 2022 | 62.47 Mn |
| Dec 31, 2021 | 88.29 Mn |
| Sep 30, 2021 | 111.90 Mn |